Background: Integrin ␣1␤1 binding to collagen IV down-regulates collagen synthesis, but how modulating integrin ␣1␤1 affinity alters collagen homeostasis is unknown. Results: Cells carrying mutations of the ␣1 subunit with enhanced collagen binding show increased ERK activation and increased collagen down-regulation. Conclusion: Enhancing the affinity of the ␣1 subunit to collagen potentiates integrin ␣1␤1-mediated outside-in signaling. Significance: These findings have major implications for pathological conditions such as fibrotic diseases.
Fibrosis, the process by which tissues are replaced by extracellular matrix, is an irreversible event that leads to loss of tissue and organ functions. Interactions between cells with the surrounding extracellular matrix have emerged as a key factor involved in the initiation and progression to fibrosis (1) . Integrins ␣1␤1 and ␣2␤1 are the key extracellular matrix receptors that regulate collagen turnover in many organs, including skin (2, 3) and kidneys (4, 5) . These integrins bind to collagens via their extracellular domains, resulting in the activation of intracellular signaling pathways via their cytoplasmic tails. Integrin ␣1␤1 activation results in the down-regulation of endogenous collagen synthesis, whereas integrin ␣2␤1 activation promotes collagen synthesis (2, 6) . Integrin ␣1␤1 is the best studied collagen receptor in the context of fibrosis. We demonstrated previously that integrin ␣1-null mice develop more severe renal fibrosis following injury, characterized by excessive deposition of collagen IV and generation of reactive oxygen species (4, 7) . The protective role of integrin ␣1␤1 resides in its ability to down-regulate the activation of the pro-fibrotic EGF receptor (8) as well as regulate the level and phosphorylation state of caveolin-1, a scaffolding protein that negatively regulates EGF receptor activation (9, 10) . Thus, integrin ␣1␤1 is a negative regulator of collagen production, and its engagement is beneficial in the setting of fibrosis.
One of the unique features of the integrin ␣1 and ␣2 subunits is that their extracellular domains contain an insertion of ϳ200 amino acids called the inserted (I) 3 domain. X-ray crystallography of the ␣2 I domain revealed that this domain consists of a central hydrophobic ␤-sheet surrounded by seven amphipathic ␣-helices with a metal ion-dependent adhesion site motif at the top of the ␤-sheet (11), which forms the major site for ligand binding (12) . The I domain confers ligand specificity; studies on isolated I domains show that the ␣1 I domain preferentially binds to collagen IV, whereas the ␣2 I domain preferentiality binds to collagen I (13) (14) (15) . In addition, the integrin ␣1 I domain binds, although with lower affinity, to collagen I and laminin-111, -211, and -511 (16 -18) . The use of chimeric ␣1/␣2 I domains demonstrates a role for the ␣3, ␣5, and a portion of the ␣6 helices within the ␣1 I domain in regulating collagen IV binding (16) . Point mutation studies of the ␣1 I domain have suggested that Glu 317 on helix ␣7 forms a salt bridge with Arg 287 on helix ␣C, thus keeping the ␣1 I domain in a closed/low affinity state. Mutating Glu 317 into an alanine results in a gain of function with increased binding affinity to both collagens I and IV (17) . Moreover, when Arg 218 in the ␣1 I domain (in the loop between helices ␣3 and ␣4) is mutated to alanine, it leads to decreased affinity to collagen IV, suggesting that Arg 218 plays an important role in determining binding specificity to collagen IV (17) . Although these data indicate that more than one amino acid is necessary for determining the specificity of the ␣1 I domain to its natural ligand, the contribution of Arg 287 in keeping the ␣1 I domain in a closed/low affinity conformation, as well as whether the salt bridge between Arg 287 and Glu 317 is indeed responsible for keeping the ␣1 I domain in a low affinity conformation has not been analyzed. Most importantly, how modulating the affinity of integrin ␣1␤1 to collagen IV results in integrin ␣1␤1-dependent alterations of collagen IV homeostasis has not been explored.
In this study we performed mutagenesis studies in combination with molecular modeling and nuclear magnetic resonance spectroscopy to delineate the molecular mechanisms that modulate integrin ␣1␤1 affinity and integrin-mediated cell function. We show that an E317A substitution resulted in a gain-offunction mutant with increased affinity to both collagens I and IV, as reported previously (17) . However, we show that a R287A substitution increased affinity to collagen I but did not change affinity to collagen IV. Surprisingly, charge reversal of Arg 287 and Glu 317 (R287E/E317R) resulted in a gain-of-function mutant. Molecular modeling and nuclear magnetic resonance spectroscopy of wild type and E31A ␣1 I domains indicated that eliminating the Glu 317 negative charge was sufficient to favor an activate conformational change. This novel result suggests that key roles played by Glu 317 are largely independent of its interaction with Arg 287 as a salt bridge. Finally, we demonstrate that cells expressing E317A or R287E/E317R substitutions show not only increased binding to collagen IV but also enhanced downregulation of endogenous collagen synthesis, which is mediated by the ERK/MAPK signaling pathway. Thus, modulating integrin ␣1␤1 affinity to collagen plays a key role in altering endogenous collagen synthesis. Altogether, these results suggest that increasing the affinity of the ␣1 I domain to its natural ligand results in enhanced outside-in signaling. Our findings identify a novel mechanism whereby integrin ␣1␤1 signaling is regulated, which has major implications for pathological conditions such as fibrotic diseases.
EXPERIMENTAL PROCEDURES
Antibodies-Anti-human integrin ␣1 TS2/7 and anti-FAK antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Hamster anti-mouse CD49a (integrin ␣1 chain), hamster anti-mouse CD49b (integrin ␣2 chain), and rabbit anti-mouse collagen IV were purchased from BD Biosciences. Mouse anti-human integrin ␣1 (mAb 1973) antibodies were obtained from Chemicon (Temecula, CA). Anti-ERK and anti-phospho-ERK antibodies were purchased from Cell Signaling (Danvers, MA). Mouse anti-vinculin (V9264) antibodies were purchased from Sigma-Aldrich.
Generation and Purification of the Human Integrin ␣1 I Domain Mutants-The human integrin ␣1 I domain (residues 140 -336 of the mature integrin ␣1 subunit (16)) (supplemental Fig. 1A ) was subcloned into a pET27 (Novagen) derived from the expression vector pBG101 (Vanderbilt Center for Structural Biology) to produce an N-terminal His 6 -GST fusion protein. This vector was used as a template for the generation of the integrin ␣1 I domain mutants using a QuikChange kit (Stratagene). Primers used for mutagenesis were as follows: R218D mutant (forward, 5Ј-GTCCAGAGAGGTGGCGACCAGAC-TATGACAGC-3Ј; reverse, 5Ј-GCTGTCATAGTCTGGTCG-CCACCTCTCTGGAC-3Ј); T220A mutant (forward, 5Ј-TGG-CCGCCAGGCTATGACAGCTCTTGGAATAG-3Ј; reverse, 5Ј-CTATTCCAAGAGCTGTCATAGCCTGGCGGCCAC-3Ј); R287A mutant (forward, 5Ј-GCTATTCTTGGCAGCTA-TAACGCAGGAAATTTAAGCACTG-3Ј; reverse, 5Ј-CAGT-GCTTAAATTTCCTGCGTTATAGCTGCCAAGAATAGC-3Ј); E317A mutant (forward, 5Ј-CTTCAATGTCTCTGATGC-ATTGGCTCTAGTCACC-3Ј; reverse, 5Ј-GGTGACTAG-AGCCAATGCATCAGAGACATTGAAG-3Ј); R287E mutant (forward, 5Ј-GCTATTCTTGGCAGCTATAACGAAGGAA-ATTTAAGCACTG-3Ј; reverse, 5Ј-CAGTGCTTAAATTTC-CTTCGTTATAGCTGCCAAGAATAGC-3Ј); E317R mutant (forward, 5Ј-CTTCAATGTCTCTGATAGATTGGCTCTAG-TCAC-3Ј; reverse, 5Ј-GGTGACTAGAGCCAATCTATCAG-AGACATTGAAG-3Ј). The fusion proteins were overexpressed in Escherichia coli BL-21(DE3) cells (Novagen) in LB medium supplemented with 30 g/ml kanamycin and 0.5 mM isopropyl-1-thio-␤-D-galactopyranoside for 16 -24 h at 16°C. The cells were suspended in 50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 10 mM imidazole, 20% (v/v) glycerol, and 2 mM ␤-mercaptoethanol and lysed with an Emusilflex C3 homogenizer (Avestin). Proteins were purified using Ni-NTA (Qiagen) affinity chromatography followed by on-column PreScission Protease (GE Healthcare) cleavage overnight at 4°C (supplemental Fig. 1B) . Mutant proteins were further purified over a 320-ml Superdex 200 gel filtration preparative grade column (GE Healthcare) equilibrated in 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 10% (v/v) glycerol, and 1 mM dithiothreitol. The yield of purified wild type (WT) and mutant ␣1 I domains was ϳ10 mg/liter culture.
Cell Culture-Immortalized mesangial cells were isolated from integrin ␣1-null mice crossed onto the Immortomouse background as described previously (8) and propagated at 33°C in the presence of 100 IU/ml ␥-interferon. Cells were cultured at 37°C without ␥-interferon for at least 4 days prior to exper-iments, as this is the optimal time for immortalized mesangial cells to acquire a phenotype similar to that of freshly isolated primary mesangial cells (8) .
Generation of Mesangial Cells Expressing the Human Integrin ␣1 I Domain Mutants-The wild type full-length integrin ␣1 cDNA was digested with BamHI and EcoRI to generate a 2.7-kb fragment containing the I domain. This fragment was subcloned into pBluescript vector and used as a template to generate the ␣1 I domain mutants described above. The mutants were then released from pBluescript by BamHI and EcoRI digestion and subcloned into pcDNA3.1 vector. For the generation of integrin ␣1-null mesangial cells expressing the various integrin ␣1 I domain mutants, cells were transfected with an empty pcDNA3.1 vector or the various cDNA constructs using Lipofectamine Plus reagent (Invitrogen) followed by Zeocin selection (Sigma-Aldrich) according to the manufacturer's instructions. Stable cell populations of ␣1-null mesangial cells expressing equal levels of the various mutants were selected by fluorescence-activated cell sorting using antibodies recognizing the extracellular I domain of human integrin ␣1 subunit (TS2/7). Polyclonal cell populations were used to avoid some of the pitfalls associated with isolation of monoclonal cell lines.
Preparation of the Collagen IV ␣1␣2␣1 Truncated ProtomerPeeled bovine lens capsules were suspended in 1 M NaCl plus protease inhibitors and then sonicated and centrifuged to remove connective tissues. The clear lens capsules (ϳ3 mg) were digested with 100 g/ml thermolysin (protease type X, Sigma-Aldrich) in TBS buffer with 2 mM CaCl 2 at 14°C. After 24 h, the digested mixture was centrifuged at 14,000 rpm at 4°C for 15 min, and the supernatant was collected followed by the addition of EDTA (10 mM final) and NaCl (1.8 M final). After a 4-h incubation at 4°C, the mixture was centrifuged at 14,000 rpm at 4°C for 15 min, and the pellet was collected and dissolved in TBS buffer containing 0.02 N acetic acid. The ␣1␣2␣1(IV) truncated protomer was purified by FPLC gel filtration chromatography using a Superdex S200 column (GE Healthcare) in TBS buffer (pH 7.4). In certain experiments, the ␣1␣2␣1(IV) truncated protomer was further digested with pepsin (Sigma) in 0.1 M acetic acid at a 1:100 ratio to remove noncollagenous (NC1) domain hexamers or with bacterial collagenase (CLSPA grade, Worthington) at a 1:100 ratio to remove the collagenous domain of the protomer.
Collagen Biotinylation-The ␣1␣2␣1(IV) truncated protomer and rat tail collagen I (BD Biosciences) were biotinylated using EZ-Link NHS-PEG4-biotin (Thermo Scientific) following the manufacturer's protocol after rapid buffer exchange to phosphate-buffered saline (PBS) using centrifugal ultrafiltration filters (Millipore, MWCO 10 kDa). Labeled proteins were purified from an excess of biotinylation reagent using a PD-10 gel filtration column (GE Healthcare), equilibrated, and eluted with TBS buffer. Efficiency of labeling was verified by Western blotting and ELISA using avidin conjugated with alkaline phosphatase (Sigma).
FACS Analysis-To determine the ability of the ␣1␣2␣1(IV) truncated protomer to bind cells in suspension, biotinylated protein (2.5 g/ml) was preincubated with avidin-FITC (5 g/ml) in the presence of 1 mM MgCl 2 for 1 h and then added to mesangial cells in suspension. In some experiments, mesangial cells were preincubated with hamster anti-integrin ␣1 or hamster anti-integrin ␣2 antibodies (30 g/ml, final) before incubation with biotinylated ␣1␣2␣1(IV) truncated protomer. Cells incubated with avidin-FITC alone were used as negative control. After 1 h, cells were washed and analyzed with a FACScan (BD Biosciences). To determine the cell surface expression of the various integrin ␣1 I domain mutants, mesangial cells were incubated with anti-human integrin ␣1 antibodies (TS2/7) for 45 min, washed, and then incubated with the appropriate phycoerythrin-conjugated secondary antibodies and analyzed with a FACScan (BD Biosciences). Data collected in flow cytometry experiments were analyzed using CellQuest software (BD Biosciences).
Solid Phase Binding-Microtiter 96-well plates (Maxisorb, Nunc) were coated overnight at 4°C with 10 g/ml mouse EHS (Engelbreth-Holm-Swarm) collagen IV (BD Biosciences), fibronectin (Sigma-Aldrich), ␣1␣2␣1(IV) truncated protomer, pepsin-digested truncated protomer, collagenase-digested truncated protomer, or ␣1␣2␣1(IV) NC1 hexamers in TBS. The plates were washed and incubated with 1% BSA in TBS to block nonspecific binding. After 1 h, the plates were washed and incubated for 2 h at 30°C with purified integrin ␣1␤1 (Chemicon, 2 g/ml) or integrin ␣v␤3 (Chemicon, 2 g/ml) in TBS with 1 mM MgCl 2 , 0.2 mM MnCl 2 or in TBS with 10 mM EDTA. After washing, the plates were incubated with anti-integrin ␣1 (Santa Cruz Biotechnology, 1:5000)-or ␣v␤3 (Chemicon, 1:5000)-specific monoclonal antibodies for 1 h followed by anti-mouse secondary antibodies conjugated to alkaline phosphatase (Sigma, 1:2000) in TBS supplemented with 1 mM MgCl 2 , 0.2 mM MnCl 2 or with 10 mM EDTA. After 1 h at 30°C, the plates were washed and incubated with p-nitrophenyl phosphate and absorbance was measured with a SpectraMax microplate reader (Molecular Devices) at 405 nm. Specific binding was calculated as the difference in absorbance between wells incubated in the presence of divalent cations (1 mM MgCl 2 , 0.2 mM MnCl 2 ) and those incubated with 10 mM EDTA. Binding experiments were performed in triplicate and repeated three times.
In some experiments, wells were coated as described above with wild type and the various human integrin ␣1 I domain mutants or the human integrin ␣2 I domain (10 g/ml in 0.1 M Na 2 CO 3 /NaHCO 3 (pH 9.5)) followed by biotinylated ␣1␣2␣1(IV) truncated protomer or biotinylated collagen I (0 -2 g/ml in TBS with or without 1 mM MgCl 2 ) followed by avidin plus HRP-conjugated biotin (Bio-Rad, 5 g/ml). Binding was detected by incubating the wells with HRP substrate and reading the plates at 595 nm with a microtiter plate reader. Collagen bound to 3% BSA-coated wells was used as background, and this optical density was subtracted from that obtained in the experimental wells. Three independent experiments were performed in quadruplicate.
To verify that the various integrin ␣1 I domains coated the wells equally, wells were coated as indicated above with wild type or the ␣1 I domain mutants (10 g/ml) followed by mouse anti-human integrin ␣1 antibody (mAb 1973, 2 g/ml) followed by anti-mouse IgG antibodies conjugated to HRP. Three independent experiments were performed in triplicate (supplemental Fig. 1C ).
Cell Adhesion-Cell adhesion was performed as described previously (4) . Briefly, U-bottom 96-well plates were coated at 4°C with ␣1␣2␣1(IV) truncated protomer or collagen I (10 g/ml in 0.1 M Na 2 CO 3 /NaHCO 3 (pH 9.5)). After 12 h, the plates were washed, and nonspecific binding sites were blocked with 1% BSA in PBS. After 1 h at 37°C, the plates were washed and 100-l cell suspensions (5 ϫ 10 4 cells in serum-free medium supplemented with 0.25% BSA) were added to the wells. After a 1-h incubation at 37°C, nonadherent cells were removed, and the attached cells were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and lysed with 10% acetic acid. Cell adhesion was quantified by reading the plates at 595 nm with a microtiter plate reader. The absorbance of the wells coated with 1% BSA only was subtracted from each well. Three experiments were performed in triplicate.
Cell Proliferation-Mesangial cells (5 ϫ 10 3 /well) were plated in low serum (1% fetal calf serum) onto 96-well plates coated with ␣1␣2␣1(IV) truncated protomer or collagen I (10 g/ml, both). After 12 h, the cells were gently washed and incubated with serum-free medium with or without the MEK inhibitor PD98059 (10 M) in the presence of [ 3 H]thymidine (0.5 Ci/well). After 48 h, the cells were collected, and the amount of incorporated [
3 H]thymidine was analyzed with a Beckman ␤-counter. Four independent experiments were performed in quadruplicate.
Cell Spreading-Mesangial cells (3,000/well) were plated in serum-free medium onto chamber slides coated with ␣1␣2␣1(IV) truncated protomer or collagen I (10 g/ml, both). After 4 h, cells were fixed in 4% formaldehyde for 10 min and permeabilized with 0.1% Triton X-100 in PBS for 5 min. After blocking with 3% BSA in PBS, cells were incubated with rhodamine-phalloidin (1:5,000; Molecular Probes) or anti-vinculin antibodies (1:500) followed by anti-mouse antibodies conjugated to FITC (1:1000). Slides were mounted with antifade mounting medium (Vectastain, Vector Laboratories) and examined under an epifluorescence microscope (Nikon).
Western Blot Analysis-To determine the basal levels of collagen IV and ERK activation, 3 ϫ 10 4 cells were plated into 6-well plates in complete medium. After 8 h, the cells were gently washed and cultured in 0.5% serum with or without the MEK inhibitor PD98059 (10 M). After 48 h, the cells were gently washed and incubated in serum-free medium with or without the MEK inhibitor for a further 16 h. Cells were then lysed in 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, and 1% sodium deoxycholate. Equal amounts of total proteins (20 g/lane) were resolved in 8% SDS-PAGE, transferred onto nitrocellulose, and then probed with anti-mouse collagen IV or anti-phospho-ERK. Immunoreactive proteins were visualized with an appropriate HRP-conjugated secondary antibody and an ECL kit. Membranes were stripped and reblotted with anti-FAK or anti-ERK antibodies to verify equal loading. Collagen IV, FAK, phospho-ERK, and ERK bands were quantified by densitometry analysis, and the collagen IV or phospho-ERK signals were expressed as the collagen IV/FAK or phospho-ERK/ERK ratio, respectively. The collagen IV/FAK or phospho-ERK/ERK ratio in control samples (i.e. integrin ␣1KO mesangial cells) was arbitrarily assigned the value of 1, and all of the other ratios were expressed as -fold changes relative to the assigned control value.
Expression and Purification of Wild Type and E317A ␣1 I Domain-Wild type and ␣1 I domain mutants were expressed from a pET-27 derivative vector as a His 6 -GST fusion protein in E. coli BL-21(DE3) cells (Novagen) grown in M9 minimal medium supplemented with 30 g/ml kanamycin. Protein expression was induced at A 600 nm ϳ0.7 by adding 0.5 mM isopropyl-1-thio-␤-D-galactopyranoside (IPTG) followed by incubation for 36 h at 16°C. The cell pellet was suspended in buffer A (50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 10 mM imidazole, 20% (v/v) glycerol, and 2 mM ␤-mercaptoethanol). Cells were lysed by sonication and the lysate clarified by centrifugation. The wild type ␣1 I domain fusion protein was purified from the clarified lysate using Ni-NTA (Qiagen) affinity chromatography and dialyzed against buffer B (50 mM Tris (pH 8.0), 300 mM NaCl, 10% glycerol, and 0.5 mM dithiothreitol (DTT)) using MWCO 15,000 Da tubing (SpectraPor 2.1 Biotech). The His-GST tag was removed by treatment with PreScission Protease (GE Healthcare) for 3 h at 4°C followed by Ni-NTA chromatography in buffer B. Mutant ␣1 I domain proteins were expressed and purified similar to the wild type but with the following minor changes to increase efficiency. Mutant protein expression was induced with 1 mM IPTG for 24 h at 16°C. Cells were lysed with an EmusilFlex C3 homogenizer (Avestin). The fusion protein was cleaved overnight on the Ni-NTA column at 4°C by incubation with PreScission Protease. The eluted proteins were concentrated using an Amicon spin concentrator (Millipore) and further purified over a 320-ml Superdex 200 gel filtration preparative grade column (GE Healthcare) equilibrated in buffer B except with 1 mM DTT. The yield of purified wild type and mutant ␣1 I domain proteins was ϳ10 mg/liter culture.
NMR Spectroscopy-15 N-Labeled ␣1 I-domain samples were expressed and purified as described above, except that expression was in 15 N-labeled M9 minimal medium. Purified proteins were buffer-exchanged into 50 mM sodium phosphate (pH 7.0), 150 mM NaCl, 5 mM DTT, 2 mM MgCl 2 , and 10% D 2 O using an Amicon Ultra-15 (MWCO 10,000 Da) centrifugal ultrafiltration concentrator. The samples were concentrated to 150 M, and sodium azide was added to 0.01%. 1 H-15 N TROSY HSQC experiments were acquired at 298 K with 32 transients/increment and 128 increments on a Bruker 800 MHz spectrometer equipped with a triple resonance cryoprobe. NMR data were processed with NMRPipe software and analyzed in Sparky.
Homology Modeling of the ␣1 I Domain Open Conformation-SWISS PdbViewer was used to thread the amino acid sequence of ␣1 I domain (residues 141-325) onto the crystal structure of the ␣2 I domain bound to a collagen-like peptide containing the GFOGER sequence (Protein Data Bank ID code 1DZI) (12) . Only 24 side chains showed steric clashes, and these were removed by energy minimization using the SWISS-MODEL web server (19) .
Statistical Analysis-Two-tailed Student's t test was used for comparisons between two groups, and analysis of variance with Sigma-Stat software was used for the determination of statistically significant differences among multiple groups. p Ͻ 0.05 was considered statistically significant.
RESULTS
Experimental Strategy-Integrins ␣1␤1 and ␣2␤1 have distinct binding affinities: ␣1␤1 has a higher affinity for collagen IV, whereas ␣2␤1 has a higher affinity for collagen I (13) (14) (15) . In the present study, we have explored the structural basis for binding affinity of integrin ␣1␤1 for collagen IV and whether modulation of the affinity influences collagen IV homeostasis. For reference purposes, binding to collagen I was compared in most experiments. The known binding site for integrin ␣1␤1 within the ␣1␣2␣1 network of collagen IV is located near the N terminus of the long triple helical protomer. This site was characterized for binding activities by excision with cyanogen bromide cleavage, yielding a triple helical fragment designated as CB3 (20, 21) . However, this fragment also harbors a binding site for integrin ␣2␤1 (20), a property that can confound studies aimed specifically at integrin ␣1␤1. Herein, we report a novel site within the ␣1␣2␣1 network of collagen IV, excised by thermolysin digestion, which binds only integrin ␣1␤1. This thermolysin-derived product was characterized and used as a tool for structure/function studies of integrin ␣1␤1.
Characterization of a Novel Integrin ␣1␤1 Binding Site in the ␣1␣2␣1 Network of Collagen IV-Our earlier studies revealed that pseudolysin digestion of the ␣1␣2␣1 network of collagen IV of lens capsule basement membrane solubilized a large truncated protomer of about 100 nm in length, representing about one-fourth of the full-length protomer, with retention of the C-terminal noncollagenous (NC1) domain and devoid of the CB3 region (22) . Pseudolysin is no longer available, but we found that thermolysin yields the same truncated protomer (supplemental Fig. 2 ). The absence of the CB3 region in the thermolysin-derived ␣1␣2␣1(IV) truncated protomer was demonstrated by the lack of a molecular weight shift under reducing conditions (supplemental Fig. 2) , which is expected for CB3-containing polypeptides because of the presence of unique disulfide knots within this region (20) . To determine whether the ␣1␣2␣1(IV) truncated protomer contains integrin ␣1␤1 binding site(s), we performed solid phase binding assays with purified integrins. As shown in Fig. 1A , integrin ␣1␤1, but not integrin ␣v␤3 (used as a negative control), bound to the immobilized ␣1␣2␣1(IV) truncated protomer. Similar results were obtained when full-length collagen IV from mouse EHS tumor was used as substrate. In contrast, integrin ␣v␤3, but not integrin ␣1␤1, bound to immobilized fibronectin.
As both integrins ␣1␤1and ␣2␤1 bind collagen IV in the CB3 region (20)
To further confirm that the ␣1␣2␣1(IV) truncated protomer contains only integrin ␣1 but not ␣2 I domain binding sites, we evaluated the ability of wild type, integrin ␣1-null, and integrin ␣2-null mesangial cells to adhere to immobilized ␣1␣2␣1(IV) truncated protomer. Whereas both wild type and integrin ␣2-null mesangial cells adhere equally to ␣1␣2␣1(IV) truncated protomer, the adhesion of cells lacking integrin ␣1␤1 was significantly impaired (Fig. 1C) . Finally, we determined by FACS the ability of biotinylated ␣1␣2␣1(IV) truncated protomer to bind mesangial cells in suspension. Similar to the adhesion data, wild type and integrin ␣2-null but not integrin ␣1-null mesangial cells bound ␣1␣2␣1(IV) truncated protomer (Fig. 1D) . Furthermore, binding of this collagen IV fragment to wild type and integrin ␣2-null cells was inhibited significantly by preincubation of cells with blocking anti-integrin ␣1 but not anti-integrin ␣2 antibodies (Fig. 1D) .
As the ␣1␣2␣1(IV) truncated protomer contains the NC1 domain and a collagenous triple helical domain, we next determined where the integrin ␣1␤1 binding site(s) resides. To do this, the ␣1␣2␣1(IV) truncated protomer was digested with either pepsin (to digest the NC1 domain) or bacterial collagenase (to digest the collagenous domain). Although pepsin treatment did not affect integrin ␣1␤1 binding, collagenase digestion completely abolished it (Fig. 1E) , suggesting that the integrin ␣1␤1 binding site resides within the collagenous triple helical domain. Thus, the thermolysin-derived ␣1␣2␣1(IV) truncated protomer contains a novel specific integrin ␣1␤1 binding site that resides within its collagenous triple helical part.
Charge Reversal of Arg 287 and Glu 317 Does Not Keep the Integrin ␣1 I Domain in a Low Affinity Conformation-Superposition of unligated ␣1 and ␣2 I domains show that the two domains are virtually identical in structure (11), yet they show differences in ligand specificity. We used the available ␣1 and ␣2 I domain crystal structures (11, 23) together with published mutagenesis studies to model sequence and structural differences between these two domains in order to identify key amino acids responsible for the binding of the ␣1 I domain to the ␣1␣2␣1(IV) truncated protomer. The following integrin ␣1 I domain mutants were generated: 1) R218D, as this amino acid is an important determinant of the binding specificity to collagen IV (17); 2) T220A, as the corresponding Thr 221 in the ␣2 I domain is important for coordinating the metal ion and binding to collagen I (24); 3) E317A and R287A, as these two amino acids form a salt bridge, thus keeping the ␣1 I domain in a closed/low affinity conformation (17); and 4) R287E/E317R, based on the assumption that charge reversal should be sufficient to keep the I domain in a closed conformation.
We performed solid phase binding to determine the ability of either the biotinylated ␣1␣2␣1(IV) truncated protomer or collagen I to bind to the various integrin ␣1 I domain mutants. As reported previously with binding to human collagen IV (17), both ␣1␣2␣1(IV) truncated protomer and collagen I bound better to the E317A mutant than to the WT ␣1 I domain (Fig. 2) . Binding of the ␣1␣2␣1(IV) truncated protomer to the R218D mutant was significantly lower than that detected for the WT ␣1 I domain ( Fig. 2A) . However, no differences in binding of collagen I to either the WT or R218D mutants were observed (Fig. 2B) . In contrast to the reported T221A mutation in the ␣2 I domain that leads to decreased adhesion to collagen I (24), binding of the ␣1␣2␣1(IV) truncated protomer or collagen I to the T220A mutant was not significantly different from binding to the WT ␣1 I domain (Fig. 2) . Two surprising results were obtained when R287A and R287E/E317R were analyzed. In contrast to the gain-of-function E317A, the R287A substitution significantly enhanced binding of collagen I with no significant changes with respect to binding of the ␣1␣2␣1(IV) truncated protomer when compared with the WT ␣1 I domain (Fig. 2) . Finally, the R287E/E317R double mutant significantly increased binding of both the ␣1␣2␣1(IV) truncated protomer and collagen I (Fig. 2) .
In conclusion, our solid phase binding assays confirm that the R218D and E317A are loss-of-function and gain-of-function mutations, respectively, with respect to ␣1␣2␣1(IV) truncated protomer binding. In addition, they reveal the following novel findings: 1) T220A does not significantly modify ␣1␣2␣1(IV) truncated protomer or collagen I binding; 2) R287A enhances collagen I binding without significantly affecting ␣1␣2␣1(IV) truncated protomer binding; and 3) the R287E/ E317R mutant, similar to the E317A mutant, is a gain-of-function mutation.
The Properties of the Various ␣1 I Domain Mutants Are Retained When the Same Mutations Are Expressed in the Fulllength ␣1
Subunit-We next generated populations of integrin ␣1-null mesangial cells expressing comparable levels of fulllength integrin ␣1 subunit carrying the mutations described above (Fig. 3A) to determine whether the changes in ligand affinity identified in the isolated ␣1 I domain mutants are retained in the context of the full-length ␣1 subunit. We performed FACS analysis to analyze the ability of these cell populations to bind biotinylated truncated protomer in suspension. Truncated protomer was used instead of commercially available collagen IV or collagen I as it carries a specific binding site for integrin ␣1␤1 (Fig. 1) . As shown in Fig. 3B , integrin ␣1-null mesangial cells expressing full-length WT integrin ␣1 (␣1-WT) bound the ␣1␣2␣1(IV) truncated protomer in solution better than parental integrin ␣1-null cells (␣1-KO). Similar to the results obtained with solid phase binding assay, no differences in ␣1␣2␣1(IV) truncated protomer binding were observed between ␣1-WT cells and ␣1-T220A or ␣1-R287A cells. In contrast, ␣1-R218D cells bound the ␣1␣2␣1(IV) truncated protomer less efficiently than ␣1-WT cells, whereas ␣1-E317A and ␣1-R287E/E317R cells bound the ␣1␣2␣1(IV) truncated protomer more efficiently than ␣1-WT cells. Cell adhesion to immobilized ␣1␣2␣1(IV) truncated protomer and collagen I was also analyzed. As shown in Fig. 3C , the binding of cells to the truncated protomer paralleled the FACS data, with ␣1-R218D cells binding to this protomer less than ␣1-WT cells, whereas ␣1-E317A and ␣1-R287E/E317R cells adhered to this protomer more than ␣1-WT cells. Cell adhesion on immobilized collagen I (Fig. 3D) revealed that ␣1-WT cells adhere more than ␣1-KO cells, and ␣1-R287A, ␣1-E317A, and ␣1-R287E/E317R cells bound more efficiently than ␣1-WT cells.
Engagement of integrins by their natural ligand leads to cell spreading and formation of focal adhesions. On the ␣1␣2␣1(IV) truncated protomer, only ␣1-WT, ␣1-R287A, ␣1-E317A, and ␣1-R287E/E317R cells spread and formed focal adhesions, as measured by vinculin staining (Fig. 4A) . On collagen I, in addition to ␣1-WT and the two gain-of-function mutants, the mutant ␣1-R287A was able to spread and recruit vinculin to focal adhesions (Fig. 4B) . Altogether these data indicate that the differences in binding of the various ␣1 I domain mutants to either the ␣1␣2␣1(IV) truncated protomer or collagen I are retained when the same mutation(s) is expressed in the full-length ␣1 subunit.
E317A-and R287E/E317R-expressing Cells Show Increased Proliferation on Both Collagen IV and
Collagen I-Activation of integrin ␣1␤1 upon binding to its natural ligand collagen IV promotes cell proliferation (25) . To determine whether modulating the affinity of integrin ␣1␤1 to collagen IV alters this cell function, we investigated the ability of the various mutant cells to proliferate on collagenous substrata. ␣1-WT cells proliferated significantly more than ␣1-KO cells when plated on the ␣1␣2␣1(IV) truncated protomer or collagen I (Fig. 5) . Cells expressing the two gain-of-function mutations (␣1-E317A and ␣1-R287E/E317R) proliferated significantly more than ␣1-WT cells on both ␣1␣2␣1(IV) truncated protomer and collagen I, whereas the ␣1-R287A cells grew more than ␣1-WT cells only when plated on collagen I (Fig. 5 ). An intermediate phenotype was observed when ␣1-R218D and ␣1-T220A cells were analyzed. Both of these cell lines proliferated significantly more than ␣1-KO cells when plated on truncated collagen IV protomer or collagen I but significantly less than ␣1-WT cells (Fig. 5) . Thus, mutations that lead either to a gain of function or increased affinity to collagen I alter cell proliferation proportionately to the ability of the cell to adhere to either ␣1␣2␣1(IV) truncated collagen IV or collagen I.
E317A -and R287E/E317R-expressing Cells Show Decreased Collagen IV Synthesis with a Concomitant Increase in ERK
Activation-Binding of integrin ␣1␤1 to its natural ligand leads to down-regulation of endogenous collagen synthesis as well as activation of ERK (2, 25) . We therefore determined whether cells expressing gain-of-function mutants down-regulate collagen IV synthesis and activate ERK more efficiently than ␣1-WT cells. ␣1-WT cells produce less collagen and have increased base-line ERK activation compared with ␣1KO cells (Fig. 6) . Interestingly, ␣1-E317A and ␣1-R287E/E317R cells revealed a more prominent decrease in collagen IV synthesis with a concomitant increase in ERK activation (Fig. 6) . Cells expressing ␣1-R218D, ␣1-T220A, and ␣1-R287A behaved similarly to ␣1-WT cells with respect to their ability to control collagen synthesis and ERK activation. Thus, increasing the ability of cells to adhere to collagen IV results in increased ERK activation and decreased collagen production.
ERK Inhibition Leads to Decreased Cell Proliferation and Increased
Collagen Synthesis-To determine whether the significant increase in ERK activation observed in the ␣1-E317A and ␣1-R287E/E317R cells regulates both proliferation and collagen synthesis, we analyzed the effect of the MEK inhibitor PD98059 on these cell functions. Treatment with 10 M PD98059 significantly decreased the proliferation of ␣1-WT, ␣1-E317A, and ␣1-R287E/E317R cells (Fig. 7A) with a concomitant inhibition of ERK phosphorylation (Fig. 7, B and C) . As no significant changes in cell proliferation were observed when ␣1-KO cells were treated with the same dose of the MEK inhibitor (Fig. 7A) , we excluded the possibility of cytotoxic effects. In contrast to proliferation, treatment with the MEK inhibitor led to a significant increase in collagen IV synthesis in ␣1-WT, ␣1-E317A, and ␣1-R287E/E317R cells (Fig. 7, B and C) . Thus, our data indicate that the ability of gain-of-function mutants to drive proliferation and down-regulate collagen synthesis is dependent on the degree of ERK activation.
The E317A Mutation Perturbs the Conformation of the ␣1 I Domain-Activation of the ␣1 I domain to the high collagen IV affinity form has been attributed to a shift in the position of helix ␣7 that releases the Arg 287 -Glu 317 salt bridge linking he- lices ␣7 and ␣C, resulting in the unwinding of ␣C (17). The E317A substitution in the ␣1 I domain enhances collagen binding (17), presumably as a result of disruption of the Arg 287 -Glu 317 salt bridge. Our binding data show that alanine and arginine substitutions at position Glu 317 result in a gain of affinity for collagen IV, suggesting that the increased binding affinity is a result of a change of the protein to the open conformation. To determine whether the E317A mutation perturbs the conformation of the ␣1 I domain, we performed 1 H-15 N TROSY HSQC NMR experiments on the WT and E317A ␣1 I domains (Fig. 8) . In this experiment, the chemical shift positions of the peaks report on the structural environment of the various amide bonds in the protein. Accordingly, these experiments are commonly used to qualitatively evaluate both the structural integrity and the conformational state of proteins. As seen in the spectra in Fig. 8 , both the WT and E317A ␣1 I domains have excellent proton chemical shift dispersion, which indicates that both are well folded. However, there are significant chemical shift perturbations in the spectrum of the E317A mutant relative to the spectrum of the WT ␣1 I domain. Given that both the E317A mutant and the WT domain are well folded and that the sample conditions are identical (see "Experimental Procedures"), the significant and widespread changes in resonance chemical shift positions must result from differences in the conformational states between the E317A mutant and the WT domain. These results are consistent with, although not definitive of, the hypothesis that the WT ␣1 I domain resides in a closed/low affinity conformation, whereas the E317A mutant may adopt an open/high affinity state by disrupting the proposed salt bridge with Arg 287 .
DISCUSSION
The goals of this study were to define the key amino acids involved in the binding of the integrin ␣1 I domain to its natural ligand, collagen IV, and to determine whether altering the affinity of integrin ␣1␤1 to collagen IV would affect integrin ␣1␤1-dependent regulation of cell function. We investigated the ability of integrin ␣1␤1 to regulate collagen homeostasis, as increased collagen production is the hallmark of all fibrotic diseases and integrin ␣1␤1 plays a protective role in the course of fibrosis by negatively regulating collagen synthesis.
Nine mammalian integrin ␣-subunits contain an I domain (26) . All ␣ I domains have a typical Rossmann fold in which a central ␤-sheet is surrounded by seven ␣-helices forming a divalent metal binding site, referred to as a metal ion-dependent adhesion site (MIDAS) (27) . In the ␣ I domains, the natural ligands are in direct contact with Mg 2ϩ coordinated by residues forming the MIDAS (28) . These ␣ I domains have a very dynamic structure, especially during ligand-induced integrin activation when the conformation changes from a close to an open state (11) . Although the ␣ I domains share highly conserved structural similarity, it has been proposed that the small differences present within the 200 amino acids may provide specific ligand binding characteristics for different integrins (18, 29 -31) . The integrin ␣1 I domain preferentially binds collagen IV, although binding to laminin-111, -211, and -511 has been also reported (17) . Arg 218 in the ␣1 I domain has been reported as an important determinant of the binding specificity to collagen IV (17) . Glu 317 in the helix ␣7 forms a salt bridge with Arg 287 in the helix ␣C, thus keeping the ␣1 I domain in the closed/low affinity conformation (17) . However, the contribution of Arg 287 , and whether the salt bridge between the helices ␣C and ␣7 plays indeed a role in keeping the integrin ␣1 I domain in the closed conformation, has not been investigated. To address these issues and to identify key amino acids able to bind the thermolysin-derived ␣1␣2␣1(IV) truncated protomer we generated various ␣1 I domain mutants. When we examined the effects of the R218D mutant binding to the ␣1␣2␣1(IV) truncated protomer, we found its affinity was decreased, thus confirming results of recent binding studies of the same mutant to human collagen IV (17) . We also confirmed that the E317A substitution resulted in a gain-of-function mutant with increased affinity for the ␣1␣2␣1(IV) truncated protomer and collagen I, suggesting a key role for Glu 317 in keeping the ␣1 I domain in a close conformation (17) .
Studies from the ␣2 I domain suggest that Thr 221 resides in proximity to the MIDAS and is critically important for coordinating the metal ion and binding to collagen I (24) . Whether the corresponding Thr 220 in the ␣1 I domain also coordinates the metal ion and binding to collagen IV has not been evaluated. We show that an integrin ␣1 I domain carrying the T220A substitution binds to the ␣1␣2␣1(IV) truncated promoter similar to the WT ␣1 I domain. Similarly, integrin ␣1-null cells expressing the T220A mutant do not show any difference in their ability to bind the ␣1␣2␣1(IV) truncated promoter when compared with ␣1-WT cells. This surprising result suggests that, unlike the Thr 221 residue in the ␣2 I domain, Thr 220 in the ␣1 I domain is not important for coordinating the metal ion and binding to collagen IV. Activation of the ␣1 I domain to the open form has been attributed to a shift in the position of helix ␣7 and concomitant release of the Arg 287 -Glu 317 salt bridge linking helices ␣7 and ␣C, resulting in the unwinding of ␣C (Fig. 9A) . The expectation, therefore, was that charge reversal of the R287E/E317R mutant should retain this interaction and have no or little effect on collagen binding. Indeed, molecular models we constructed from the existing ␣1 and ␣2 I domains indicated that this electrostatic interaction could easily be accommodated in the R287E/E317R double mutant. However, we provided functional and structural evidence that both E317A and R287E/ E317R mutations result in gain-of-function conformation mutants, demonstrating that elimination of the negative charge in Glu 317 is sufficient for increased activity of the mutant. Our NMR results confirmed that the E317A mutant adopts a different conformation than to the WT ␣1 I domain, and the extent of chemical shift differences between the WT and E317A spectra shown in Fig. 8 is consistent with a significant shift difference between helix ␣7 and associated global structural changes toward open conformation (12) . It is surprising, therefore, that this helix was unperturbed in a recent crystal structure of the ␣1 I domain containing a double C139S/E317A substitution (32) . This inconsistency may be due to the different experimental conditions used in the NMR and crystallization experiments and the fact that the crystal lattice may impose a constraint that favors a conformation that is likely to be only one of multiple interconverting conformations present under solution.
The activating conformational change resulting from elimination of the Glu 317 negative charge can be rationalized on the basis of the crystal structures of the open and closed forms of the ␣1 and ␣2 I domains (11, 12, 23) and the model proposed in Fig. 9 . In the closed form, the negatively charged Glu 317 side chain is well positioned to undergo a favorable monopole/helical dipole interaction with helix ␣7 and perhaps also with helix ␣1, both of which have their N3 C dipole moments aligned in a parallel orientation. Thus, disruption of this negative charge in any Glu 317 mutant (i.e. E317A or E317R) would abrogate any favorable monopole/dipole interaction, stabilizing the position of helix ␣7, and may even increase electrostatic repulsion between ␣7 and ␣1 dipoles, consequently destabilizing the closed form and shifting the equilibrium toward the higher affinity open form. In addition, substitution of the glutamate side chain will disrupt stabilizing interactions proximal to the MIDAS. Furthermore, electrostatic interactions between the Glu 317 side chain and Asp 167 on helix ␣1 may also influence the switch between open and closed conformations (Fig. 9, B-D) .
We also provide evidence that the R287A substitution leads to increased affinity toward collagen I and unchanged affinity toward collagen IV. The differential binding of the R287A mutant toward collagens I and IV is likely a result of the fact that in the open form Arg 287 is exposed to the collagen binding surface, suggesting that this residue directly contacts collagen in the bound form in a way that it is collagen IV-specific. Taken together, these data suggest that the key roles played by Arg 287 and Glu 317 seem to be largely independent of their interaction as a salt bridge.
A key question addressed in this study was whether changes in affinity observed in the isolated mutated I domains were retained in the context of the full-length ␣1 subunit in cells. This is important, as cells expressing the single D219N or D292N substitution in the ␣2 I domain are still able to bind collagen I, despite the loss of binding in the isolated ␣2 I domain carrying the same mutations (33) . On the other hand, mutation of the Thr 221 in the ␣2 I domain results in loss of adhesion to collagen I in the isolated ␣2 I domain as well as when it is expressed in the full-length integrin ␣2 subunit (34) . Finally, the E317A substitution in the ␣1 I domain results in a domain with increased binding to both collagens I and IV, an effect that is maintained when the same mutation is expressed in the whole integrin ␣1 subunit in cells (32) . Thus, it is clear that not all mutations that alter the binding of the ␣1 I domain to its natural ligand result in the same changes in the context of the whole integrin. We have provided evidence that integrin ␣1-KO cells expressing the R287A and T220A mutations, as well as the two gain-of-function E317A and R287E/E317R mutations, adhere to either the ␣1␣2␣1(IV) truncated protomer or collagen I with the same pattern as observed with the isolated I domains, suggesting that expressing the mutation in the full integrin ␣1 subunit does not change the ligand specificity.
Finally, another key point we addressed in this study was whether modulating the affinity to ligand affected integrin ␣1␤1-mediated cell function. Upon binding to their natural ligand, integrins activate intracellular pathways controlling different cell functions, including cell proliferation, migration, differentiation, and matrix homeostasis. The best characterized mechanisms of integrin-mediated signaling are those mediated by their cytoplasmic tails. Integrin ␣1subunit has a short cytoplasmic tail consisting of 15 amino acids, and truncation and point mutants have revealed a role for specific amino acids within the tail in controlling selective cell functions (10, (35) (36) (37) . In addition, the transmembrane domains of integrins have been shown to play a key role in integrin activation as well as outside-in signaling. In this context, mutations that disrupt the interaction between integrin ␣IIb and ␤3 transmembrane domains result in the activation of intracellular signaling pathways (38) . Moreover, we have demonstrated that substitution of the transmembrane domain of the integrin ␣2 subunit with that of ␣1 results in decreased cell adhesion, migration, and tubulogenesis, clearly suggesting a role for the integrin ␣2 transmembrane domain in regulating cell functions (37) . In this study, we demonstrated that altering the affinity of the integrin ␣1 I domain to collagen affected ␣1␤1-mediated intracellular signaling. Integrin ␣1-KO cells carrying mutations within the ␣1 I domain that enhance binding to both the ␣1␣2␣1(IV) truncated protomer and collagen I (i.e. E317A and R287E/ E317R) have a significantly increased ERK activation compared with cells carrying WT or loss-of-function mutant ␣1 I domains. We further showed that ␣1-KO cells carrying the E317A or R287E/E317R substitutions proliferate significantly more than ␣1-KO or ␣1-WT cells, suggesting that enhanced ERK activation in these mutant cells leads to robust cell proliferation. These results are consistent with our previous findings that ligated integrin ␣1␤1 activates the Shc/Grb2/ERK signaling pathway, which promotes cell proliferation, and that cells lacking integrin ␣1␤1 fail to activate this mitogenic pathway and to proliferate when plated on collagen IV (25) .
ERK not only promotes proliferation but also plays a role in regulating collagen synthesis. ERK can be pro-fibrotic as seen in (23) . The open form was constructed by homology modeling as described under "Experimental Procedures" using as a template the crystal structure of the ␣2 I domain bound to a collagen-like peptide containing the GFOGER sequence (Protein Data Bank ID code 1DZI) (12) . B and C, schematic of parallel helices ␣1 and ␣7 in WT (B) and E317R (C, left) and E317A (C, right). the situation of increased mechanical load, which induces ERK activation, a key step in promoting collagen I expression (39) . In contrast, it has been shown recently that matrix-induced activation of the MEK/ERK pathway promotes inhibition of collagen I synthesis (40) . We previously showed that binding of integrin ␣1␤1 to collagen IV results in the down-regulation of collagen IV and that cells lacking this collagen receptor show increased basal levels of endogenous collagen IV (2, 4, 8) . Our current finding that cells that express ␣1 I domain mutants, which are able to promote sustained ERK activation, show enhanced down-regulation of endogenous collagen IV synthesis, suggesting a key role for ERK activation in mediating the down-regulation of collagen IV synthesis.
In conclusion, we have demonstrated that increasing the affinity of the extracellular domain of the integrin ␣1 I domain to its natural ligand enhances activation of intracellular kinases and, most importantly, down-regulation of collagen synthesis. This finding has major implications for our understanding of the pathogenesis of fibrotic disease and suggests that targeting collagen receptors may be a therapeutic strategy to halt the progression of this ubiquitous pathological process.
